Werewolf Therapeutics
HOWL
38 hedge funds and large institutions have $42.8M invested in Werewolf Therapeutics in 2022 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 10 increasing their positions, 9 reducing their positions, and 13 closing their positions.
11% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 9
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
3.08% less ownership
Funds ownership: 70.97% → 67.89% (-3.1%)
14% less funds holding
Funds holding: 44 → 38 (-6)
38% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 13
55% less capital invested
Capital invested by funds: $94.5M → $42.8M (-$51.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$4M |
| 2 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$2.27M |
| 3 |
Millennium Management
New York
|
+$855K |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$265K |
| 5 |
Renaissance Technologies
New York
|
+$157K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$4.32M |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$3.98M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.52M |
| 4 |
PIM
Platinum Investment Management
Sydney Australia 2000,
Australia
|
-$494K |
| 5 |
BlackRock
New York
|
-$286K |
HOWL Hedge Fund Activity: Q4 2022 in Review
38 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Werewolf Therapeutics (HOWL) for Q4 2022, worth a combined $42.8M — down 55% from $94.5M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of HOWL and 8 opened new positions — a net loss of 5 holders — while 9 trimmed existing stakes and 10 added.
The largest buyer was Bank of America, adding an estimated $4M. The largest seller was Deerfield Management, exiting entirely with an estimated $4.32M sold.
- 38 institutional investors held Werewolf Therapeutics (HOWL) as of Q4 2022, down from 44 in Q3 2022.
- Funds reported $42.8M of Werewolf Therapeutics stock for Q4 2022, down 55% quarter-over-quarter.
- 8 funds opened new Werewolf Therapeutics positions in Q4 2022 and 13 closed out, a net change of -5 holders.
- The largest Werewolf Therapeutics buyer in Q4 2022 was Bank of America, an estimated $4M added.
- The largest Werewolf Therapeutics seller in Q4 2022 was Deerfield Management, an estimated $4.32M sold.
Based on aggregated 13F filings for Q4 2022.